Amaranth Presented MAGNITUDE (98 micron) Nine-Month Follow-up Clinical Results and Introduced DEFIANCE (85 micron) BRS Development Plan at TCT
September 24, 2018 07:59 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds, provided an update on the company’s...
Amaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR Symposium
May 23, 2018 08:30 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , May 23, 2018 (GLOBE NEWSWIRE) -- Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds for the interventional cardiology market, provided...
Amaranth Medical Showcases Breadth of BRS Pipeline at TCT, Unveiling 9-mo Interim Imaging Results from 98 micron MAGNITUDE and Update on 115-micron APTITUDE
October 25, 2017 13:21 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds for the interventional cardiology market, will...
Amaranth Medical Initiates Trial of Sub-100-Micron MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold
November 01, 2016 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , Nov. 01, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced the initiation of a clinical study of the Company’s latest-generation...
Amaranth Medical 9-Months Clinical and Imaging Results of the FORTITUDE Sirolimus-Eluting Bioresorbable Scaffold Presented at TCT
October 31, 2016 12:30 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that a presentation of the 9-month clinical and imaging results from the...
Amaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE™ Sirolimus-Eluting Bioresorbable Scaffold
June 06, 2016 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , June 06, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that it completed enrollment in May 2016 in the RENASCENT-II study of its...
Amaranth Medical On Track to Complete Enrollment in RENASCENT-II Study of 120-Micron APTITUDE™ Sirolimus-Eluting Bioresorbable Scaffold in May
May 18, 2016 03:01 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , May 18, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, provided a clinical update on its ongoing RENASCENT-II study of its novel APTITUDE™...
Amaranth Medical Completes MEND-II and RENASCENT Studies and Initiates Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold
October 15, 2015 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that enrollment has successfully concluded in its multi-center, international...
Amaranth Medical Reports Findings from Two FORTITUDE Bioresorbable Scaffold Studies at EuroPCR 2015
May 18, 2015 15:12 ET
|
Amaranth Medical, Inc.
Mountain View, CA, May 18, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a
privately held medical device company, announced plans to report
clinical results from the Company's ongoing trial of...
Amaranth Medical Initiates Clinical Trial of the Second-Generation FORTITUDE Bioresorbable Drug-Eluting Scaffold
September 16, 2014 09:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Sept. 16, 2014 (GLOBE NEWSWIRE) -- Amaranth Medical, a
privately held medical device company, announced the initiation of
patient enrollment in multiple centers in Colombia, South...